Diseases [C] » Nervous System Diseases [C10] » Neuromuscular Diseases
Description
A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA. MeSH
Hierarchy View
Subtype Terms (8)
Fatigue Syndrome, Chronic
70 drugs (42 approved, 28 experimental)
Motor Neuron Disease
23 drugs (14 approved, 9 experimental)
Muscular Diseases
24 drugs (16 approved, 8 experimental)
Neuromuscular Junction Diseases
2 approved drugs
Peripheral Nervous System Diseases
88 drugs (53 approved, 35 experimental)
Poliomyelitis
53 drugs (31 approved, 22 experimental)
Stiff-Person Syndrome
14 drugs (12 approved, 2 experimental)
Phase 3 Indicated Drugs (5)
Phase 2 Indicated Drugs (4)
Phase 1 Indicated Drugs (3)
Other Experimental Indicated Drugs (4)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (14)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
